TY  - GEN
AU  - Battistella,M
AU  - Janin,A
AU  - Jean-Louis,F
AU  - Collomb,C
AU  - Leboeuf,C
AU  - Sicard,H
AU  - Bonnafous,C
AU  - Dujardin,A
AU  - Ram-Wolff,C
AU  - Kadin,M E
AU  - Bensussan,A
AU  - Bagot,M
AU  - Michel,L
TI  - KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma
SN  - 1365-2133
PY  - 2017///0724
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - pharmacology
KW  - Antineoplastic Agents
KW  - Cell Line, Tumor
KW  - Female
KW  - Humans
KW  - Ki-1 Antigen
KW  - metabolism
KW  - Killer Cells, Natural
KW  - physiology
KW  - Leukocytes, Mononuclear
KW  - Lymphoma, Large-Cell, Anaplastic
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Receptors, KIR2DL2
KW  - antagonists & inhibitors
KW  - Skin
KW  - Skin Neoplasms
KW  - Tumor Cells, Cultured
KW  - Young Adult
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1111/bjd.14626
ER  -